Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary showed mixed signals. Financial performance was positive with a 15% revenue increase and a 43% rise in net income. However, increased R&D expenses and cash decline indicate financial strain. Risks in clinical trials and ARCALYST's commercial execution add uncertainty. The market cap suggests moderate sensitivity to news, and without strong positive catalysts or partnership announcements, the overall sentiment remains neutral.
Key Financial Performance
Revenue The company reported $45 million in revenue for Q1 2026, representing a 15% increase year-over-year. This growth was attributed to strong sales of ARCALYST and expanded market penetration.
Net Income Net income for the quarter was $10 million, up from $7 million in Q1 2025, marking a 43% increase. The improvement was driven by higher revenue and effective cost management.
Research and Development Expenses R&D expenses were $20 million, a 25% increase compared to $16 million in Q1 2025. The rise was due to increased investment in the KPL-387 development program and ongoing clinical trials.
Operating Expenses Operating expenses totaled $30 million, up 20% from $25 million in the same period last year. This was primarily due to higher R&D spending and marketing costs for ARCALYST.
Cash and Cash Equivalents The company ended the quarter with $150 million in cash and cash equivalents, a decrease from $170 million at the end of Q1 2025. The decline was attributed to increased R&D and operational spending.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
KPL-387 development program: Kiniksa's Chief Medical Officer, Dr. John Paolini, reviewed the KPL-387 development program and the ongoing Phase II/III clinical trial in recurrent pericarditis.
ARCALYST commercial execution: Ross Moat, Chief Operating Officer, provided an update on ARCALYST commercial execution.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements made during the call are subject to risks, which could impact the company's performance and strategic objectives.
Clinical trial risks: The ongoing Phase II/III clinical trial in recurrent pericarditis presents risks related to trial outcomes, regulatory approvals, and potential delays.
Commercial execution of ARCALYST: Challenges in the commercial execution of ARCALYST could impact revenue generation and market penetration.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Anupam Rama
CFO Nicholas
COO Principal
Canaccord Genuity
Corp Research
Cowen Research
Division Anupam
Division EDT
Division Edward
Division Eva
Division Fiona
Division Kyuwon
Dr development
EDT day
Edward Nash
Executive VP
Fiona Huang
Genuity Corp
Huang Jefferies
Inc Research
Kyuwon Choi
LLC Research
Nash Canaccord
Nicholas Lorusso
Officer Dr
Officer Executive
Research Division
Securities
VP COO
introduction Chief
pericarditis Chief
plc Investor
trial pericarditis
KNSA Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript
Unknown4-28
The earnings call summary showed mixed signals. Financial performance was positive with a 15% revenue increase and a 43% rise in net income. However, increased R&D expenses and cash decline indicate financial strain. Risks in clinical trials and ARCALYST's commercial execution add uncertainty. The market cap suggests moderate sensitivity to news, and without strong positive catalysts or partnership announcements, the overall sentiment remains neutral.
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript
Positive2-24
The company demonstrated strong financial performance with significant revenue and net income growth, improved guidance, and robust cash generation. ARCALYST's market penetration shows potential for further growth, and KPL-387 offers promising expansion opportunities. Despite competitive pressures and vague management responses on certain aspects, the overall sentiment remains positive due to raised guidance, strong product adoption, and strategic market positioning. Given the market cap, the expected stock price movement is positive (2% to 8%).
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2025 Earnings Call Transcript
Positive10-28
The earnings call summary and Q&A indicate strong financial performance, positive feedback from patients and physicians, and increased prescriber numbers for ARCALYST. The raised sales guidance for 2025 and strategic marketing efforts further bolster the outlook. Despite some unclear management responses, the overall sentiment is positive, with a focus on growth and market penetration. Given the company's market cap, this is likely to result in a stock price increase of 2% to 8% over the next two weeks.
KNSA Slides
KNSA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
